What is the difference between Briviact and Keppra?

Both Briviact and Keppra target the synaptic vesicle protein 2A, but the newer agent Briviact is noted to be more selective and have higher affinity for this receptor than Keppra.

The differences between Briviact and Keppra are:

• Briviact is an analogue of Keppra and used with other seizure medications in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy. Keppra is also used to treat partial onset seizures in adults and children at a younger age.
• Keppra is also used to treat tonic-clonic seizures in adults and children who are at least 6 years old, and myoclonic seizures in adults and children who are at least 12 years old. Briviact is an anti-seizure medication and was FDA-approved in February 2016.
• Briviact is available in oral tablets, oral solution and in an intravenous (IV) injection. Keppra comes as regular-release or extended-release oral tablets (Keppra XR), as an oral solution, or as an IV injection.

Both Briviact (generic name brivaracetam) and Keppra (generic name levetiracetam) are used in epilepsy.

An orally-dissolving tablet form of levetiracetam known as Spritam is also available for patients 4 years and older.